Kamada Ltd.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Amir London
- Full Time Employees
- 462
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2 Holzman Street Rehovot HM Israel 7670402
- IPO Date
- May 31, 2013
- CIK
- 0001567529
- Website
- kamada.com
- Similar Companies
- Business
- Kamada Ltd. (KMDA) is a vertically integrated global biopharmaceutical company focused on the research, development, manufacturing, and commercialization of specialty plasma-derived protein therapeutics. The company offers a diverse portfolio of proprietary FDA-approved products including GLASSIA for alpha-1 antitrypsin deficiency, KEDRAB for rabies post-exposure prophylaxis, CYTOGAM for cytomegalovirus prophylaxis in transplant patients, HEPAGAM B for hepatitis B post-exposure prophylaxis, VARIZIG for varicella-zoster virus prophylaxis, and WINRHO SDF for immune thrombocytopenic purpura and Rh hemolytic disease of the newborn; it also distributes additional plasma-derived products and biosimilars in Israel. Kamada operates in more than 30 countries including the U.S., Canada, Israel, Latin America, and Asia, leveraging FDA-approved manufacturing facilities for protein separation, formulation, and filling services. Founded in 1990 and headquartered in the Weizmann Science Park in Rehovot, Israel, Kamada employs approximately 450 people and lists on NASDAQ since 2013 and the Tel Aviv Stock Exchange since 2005, with FIMI Opportunity Fund as its largest shareholder holding about 21% of shares. In recent developments, Kamada has advanced its pivotal Phase 3 InnovAATe clinical trial for inhaled alpha-1 antitrypsin to treat AAT deficiency, expanded plasma collection operations, and executed business development including strategic M&A activities; the company affirmed 2024 financial guidance with strong profitability and projected double-digit revenue growth for 2025 driven by organic commercial expansion across its offerings in over 30 nations and ongoing plasma initiatives.
Company News
Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
KMDA or PRTA: Which Is the Better Value Stock Right Now?
Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet
Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates
Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance
Kamada Announces Planned Transition of Chief Financial Officer
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
Reviewing InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA)
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting